The price of innovation: new estimates of drug development costs.

[1]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[2]  F. Scherer,et al.  The link between gross profitability and pharmaceutical R&D spending. , 2001, Health affairs.

[3]  J. DiMasi.  New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.

[4]  J. DiMasi,et al.  Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.

[5]  J. DiMasi,et al.  New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms , 2000 .

[6]  J M Reichert,et al.  New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. , 2000, Trends in biotechnology.

[7]  J. DiMasi,et al.  Measuring the Pace of New Drug Development in the User Fee ERA , 2000 .

[8]  E. M. Healy,et al.  The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era* , 2000 .

[9]  J. Wagner,et al.  HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY , 1998 .

[10]  Peck Cc.  Drug development: improving the process. , 1997, Food and drug law journal.

[11]  Drug development: improving the process. , 1997, Food and drug law journal.

[12]  R. Helms.  Competitive Strategies in the Pharmaceutical Industry , 1996 .

[13]  Henry G. Grabowski,et al.  R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry , 1995 .

[14]  Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. , 1995, PharmacoEconomics.

[15]  E. Broshy,et al.  The Contribution of Pharmaceutical Companies: What's at Stake for America , 1994, Annals of the New York Academy of Sciences.

[16]  H. Grabowski,et al.  Returns to R&D on new drug introductions in the 1980s. , 1994, Journal of health economics.

[17]  Associates Ibbotson,et al.  Stocks, bonds, bills, and inflation yearbook , 1993 .

[18]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[19]  Henry G. Grabowski,et al.  A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .

[20]  Robert I. Chien.  Issues in pharmaceutical economics , 1979 .

[21]  Intangible Capital and Rates of Return , 1977 .

[22]  David Belk,et al.  The Pharmaceutical Industry , 1965, Nature.